Related Experiment Video
Updated: Dec 3, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Methods for the Construction of Recombinant Oncolytic Myxoma Viruses
Lino E Torres-Domínguez1, Ana Lemos de Matos1, Masmudur M Rahman1
1Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Abstract:
Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.
Insights
Myxoma virus (MYXV) shows promise for oncolytic virotherapy due to its safety and adaptability. Researchers detail methods for creating engineered MYXV vectors armed with transgenes for cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Virology
- Molecular biology
Background:
- Myxoma virus (MYXV) is a promising candidate for oncolytic virotherapy.
- It is a nonhuman pathogen, avoiding pre-existing immunity.
- Its DNA does not integrate into the host genome, ensuring safety.
Purpose of the Study:
- To describe protocols for generating and characterizing transgene-armed recombinant MYXV vectors.
- To enable the development of enhanced oncolytic viruses (OVs).
Main Methods:
- Detailed protocols for recombinant MYXV vector generation.
- Characterization of MYXV vectors carrying transgenes.
Main Results:
- Established methods for creating transgene-armed MYXV.
- Demonstrated MYXV's potential for engineered oncolytic viruses.
Conclusions:
- MYXV is a safe and versatile platform for oncolytic virotherapy.
- Engineered MYXV vectors can be developed for enhanced cancer treatment strategies.
